Prognostic value of tumour volume in patients with a poor Karnofsky performance status scale - a bicentric retrospective study.
EOR
Glioblastoma
Karnofsky performance status scale
Surgery
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
15 Nov 2021
15 Nov 2021
Historique:
received:
01
11
2020
accepted:
29
09
2021
entrez:
16
11
2021
pubmed:
17
11
2021
medline:
18
11
2021
Statut:
epublish
Résumé
Median overall survival (OS) after diagnosis of glioblastoma (GBM) remains 15 months amongst patients receiving aggressive surgical resection, chemotherapy and irradiation. Treatment of patients with a poor preoperative Karnofsky Performance Status Scale (KPSS) is still controversial. Therefore, we retrospectively assessed the outcome after surgical treatment in patients with a KPSS of ≤60%. We retrospectively included patients with a de-novo glioblastoma WHO °IV and preoperative KPSS ≤60%, who underwent surgery at two neurosurgical centres between September 2006 and March 2016. We recorded pre- and postoperative tumour volume, pre- and postoperative KPSS, OS, age and MGMT promoter status. One hundred twenty-three patients (58 females/65 males, mean age 67.4 ± 13.4 years) met the inclusion criteria. Seventy-five of the 123 patients (61%) underwent surgical resection. 48/123 patients (39%) received a biopsy. The median preoperative and postoperative tumour volume of all patients was 33.0 ± 31.3 cm GBM patients with a preoperative KPSS of ≤60% might profit from surgical reduction of tumour burden.
Identifiants
pubmed: 34781889
doi: 10.1186/s12883-021-02424-0
pii: 10.1186/s12883-021-02424-0
pmc: PMC8591917
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
446Informations de copyright
© 2021. The Author(s).
Références
J Neurosurg. 2003 Sep;99(3):467-73
pubmed: 12959431
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Curr Treat Options Oncol. 2017 Oct 27;18(11):66
pubmed: 29080109
Clin Interv Aging. 2014 Feb 21;9:357-67
pubmed: 24591820
Clin Cancer Res. 2009 Nov 1;15(21):6683-93
pubmed: 19861461
J Neurosurg. 2013 Apr;118(4):801-8
pubmed: 23373806
J Neurosurg. 2011 Jul;115(1):3-8
pubmed: 21417701
CNS Oncol. 2017 Jan;6(1):19-28
pubmed: 28001088
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
J Neurooncol. 2018 Dec;140(3):623-628
pubmed: 30182159
J Clin Neurosci. 2018 Jun;52:66-70
pubmed: 29576419
J Neurooncol. 2015 May;122(3):567-73
pubmed: 25700836
J Neurosurg. 2001 Aug;95(2):190-8
pubmed: 11780887
J Neurooncol. 2015 Jan;121(2):359-64
pubmed: 25344883
Neurol Med Chir (Tokyo). 2012;52(8):570-6
pubmed: 22976140
J Neurosurg. 2003 Jun;98(6):1175-81
pubmed: 12816260
Clin Neurol Neurosurg. 2015 Sep;136:89-94
pubmed: 26092644
J Neurosurg. 2016 Apr;124(4):977-88
pubmed: 26495941
J Neurosurg. 2014 Nov;121(5):1115-23
pubmed: 25192475
J Clin Neurosci. 2013 Jun;20(6):818-23
pubmed: 23639620
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Ann Surg Oncol. 2018 Feb;25(2):558-564
pubmed: 29159745
Cancer Res. 1947 Jan;7(1):50
pubmed: 20278229
Eur J Cancer Care (Engl). 2010 Jan 1;19(1):39-44
pubmed: 19912295